Secondary pure erythroid leukaemia in relapsed acute lymphoblastic leukaemia: lineage switch or chemotherapy effect?

Gupta, Sanjeev Kumar ; Kumar, Rajive ; Chharchhodawala, Taher ; Kumar, Lalit (2014) Secondary pure erythroid leukaemia in relapsed acute lymphoblastic leukaemia: lineage switch or chemotherapy effect? BMJ Case Reports, 2014 . No pp. given. ISSN 1757-790X

Full text not available from this repository.

Official URL: http://casereports.bmj.com/content/2014/bcr-2013-2...

Related URL: http://dx.doi.org/10.1136/bcr-2013-201724

Abstract

Pure erythroid leukaemia is a rare subtype of acute myeloid leukaemia (AML) and its occurrence at acute lymphoblastic leukaemia (ALL) relapse has not been reported earlier. A 39-year-old man received chemotherapy for Philadelphia-negative B cell ALL. Subsequently, he developed pure erythroid leukaemia with >80% immature erythroid precursors in bone marrow showing block positivity on periodic acid-Schiff stain, expressing CD71, CD34 but lacking CD235a. The interval between exposure to multidrug chemotherapy including cyclophosphamide and AML diagnosis was 2 years and 9 months. No cytogenetic abnormality was detected at the time of relapse. The patient died 2 weeks after starting AML chemotherapy. The relatively narrow time interval (usually 5–10 years) between chemotherapy and AML development and normal karyotype at relapse raises a possibility of lineage switch besides therapy-related AML as the likely pathogenesis. Further exploration of such cases may unravel the pathways responsible for lineage assignment in pluripotent stem cells.

Item Type:Article
Source:Copyright of this article belongs to BMJ Publishing Group Ltd.
ID Code:111262
Deposited On:25 Sep 2017 12:37
Last Modified:25 Sep 2017 12:37

Repository Staff Only: item control page